Phio Pharmaceuticals Corp. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On November 16, 2026, Phio Pharmaceuticals Corp. received notice of failure to satisfy continued listing standards and faces delisting or transfer of listing. The filing provides no specific financial metrics, compliance violations, or remediation details. For a company with $11.2M market value, delisting represents an existential threat to its ability to raise capital and operate as a public company.
Why this rating
Delisting is business-threatening for micro-cap; jeopardizes equity financing, liquidity, and investor access. Existential risk.
Extracted items
Price action (we called it negative)
before filing · preread $0.66 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.